A regulatory affairs team manages the preparation, coordination, and submission of all documentation required to obtain and maintain marketing authorization for medicinal products and medical devices. Their role spans the entire product lifecycle, from early-stage strategy through post-approval compliance. The sections below unpack each dimension of that role in detail.
What does a regulatory affairs team actually do during a submission?
During a regulatory submission, a regulatory affairs team compiles, reviews, and coordinates all technical documentation required by health authorities. This includes writing and formatting dossiers, ensuring data integrity across modules, aligning content with current guidelines, and managing the submission process from first draft to final filing.
The work is more complex than it might appear from the outside. A submission is not simply a collection of documents handed over to an agency. The regulatory affairs team acts as the central coordinator between multiple internal functions, including clinical, CMC, pharmacovigilance, and quality assurance, making sure every section of the dossier is consistent, complete, and compliant with the applicable regulatory framework.
Key activities during a submission include:
- Drafting and reviewing Common Technical Document (CTD) modules
- Preparing cover letters, summaries, and overviews
- Coordinating timelines across contributing departments
- Performing gap analyses against current guidelines
- Managing eCTD publishing and technical validation
- Responding to agency questions and deficiency notices
The team also keeps a close eye on evolving regulatory requirements. Guidelines are updated regularly, and a submission that was compliant six months ago may need adjustments before filing today. Staying current is not optional; it is a core part of the job.
What is the difference between regulatory strategy and regulatory submissions?
Regulatory strategy is the planning phase that determines how a product should be developed and approved, while regulatory submissions are the execution phase where that plan is translated into formal applications sent to health authorities. Strategy shapes what gets submitted; submissions are the mechanism by which approval is sought.
A regulatory strategy addresses questions such as which markets to target first, which regulatory pathway is most appropriate, what data package will be required, and how to sequence interactions with health authorities. It is developed early, often before clinical trials begin, and it informs every downstream decision.
Regulatory submissions, by contrast, are the formal deliverables that result from executing that strategy. They include initial marketing authorization applications, variations, renewals, and responses to agency questions. Each submission must conform to specific formatting, content, and procedural requirements.
The two functions are deeply interconnected. A weak strategy leads to avoidable deficiencies in submissions. A well-prepared submission can still fail if the underlying strategy did not anticipate what the agency would require. Strong regulatory affairs teams integrate both capabilities and treat them as a continuous process rather than separate workstreams.
How does a regulatory affairs team interact with health authorities?
A regulatory affairs team serves as the primary point of contact between a company and health authorities such as the EMA, FDA, or national competent authorities. They manage formal communications, prepare responses to agency questions, and represent the company in scientific meetings and consultations.
This interaction takes several forms depending on the stage of development and the type of procedure involved. Before a submission, the team may request scientific advice or pre-submission meetings to align with the agency on the data package. During a review, they respond to questions, provide clarifications, and negotiate where regulatory flexibility exists. After approval, they maintain the relationship through variation notifications, periodic safety updates, and renewal applications.
Effective interaction with health authorities requires more than technical knowledge. It demands an understanding of agency culture, procedural timelines, and the specific expectations of individual reviewers. Experienced regulatory professionals know how to frame responses clearly, anticipate follow-up questions, and build a constructive working relationship with agencies over time. That relationship can make a meaningful difference in how smoothly a review proceeds.
What types of submissions does a regulatory affairs team manage?
A regulatory affairs team manages a broad range of submission types across the product lifecycle, from initial marketing authorization applications to post-approval changes, renewals, and safety updates. The specific submissions depend on the product type, the target market, and the regulatory pathway chosen.
Common submission types include:
- Marketing Authorization Applications (MAAs): Initial applications seeking approval to place a product on the market
- Variations: Changes to an approved product, ranging from minor administrative updates to major changes in manufacturing or indication
- Renewals: Periodic resubmissions required to maintain an active marketing authorization
- Periodic Safety Update Reports (PSURs): Ongoing pharmacovigilance submissions summarizing the benefit-risk profile of an approved product
- Responses to agency questions: Formal replies to deficiency lists or day-120/150 lists during review procedures
- Scientific advice requests: Pre-submission consultations with agencies to align on development plans
- Device technical files and conformity assessments: For medical devices seeking CE marking under EU MDR or IVDR
For companies working across multiple markets, the same core dossier may need to be adapted for different regulatory frameworks, each with its own formatting requirements, procedural rules, and review timelines. Managing this complexity across jurisdictions is one of the more demanding aspects of regulatory submissions work.
When should a company bring in an external regulatory affairs team?
A company should consider bringing in an external regulatory affairs team when internal resources lack the specific expertise needed, when submission timelines are tight, or when entering a new market or product category for the first time. External support is also valuable during periods of rapid growth or when a backlog of regulatory tasks risks delaying product development.
Several situations make external expertise particularly worthwhile:
- Preparing a first-in-class or complex product submission where specialized knowledge is critical
- Navigating a new regulatory framework, such as EU MDR for medical devices or the ATMP classification pathway
- Responding to agency questions under tight deadlines when internal bandwidth is insufficient
- Conducting regulatory gap analyses ahead of inspections or audits
- Supporting a small or early-stage company that does not yet have a full internal regulatory function
Bringing in external support does not mean handing over control. The best external teams work as an extension of the internal function, integrating with existing processes and providing targeted expertise where it adds the most value. Early engagement, before a submission is drafted rather than after problems emerge, tends to produce the best outcomes.
How does the regulatory affairs team support post-approval compliance?
After a product receives approval, the regulatory affairs team ensures ongoing compliance by managing post-approval variations, maintaining the dossier, submitting required safety reports, and monitoring changes in regulatory requirements that may affect the approved product. Post-approval regulatory work is continuous and often underestimated in scope.
Regulatory approval is not a finish line. It is the beginning of a long-term compliance obligation. Manufacturing changes, new clinical data, labeling updates, and evolving guidelines all require formal regulatory action. Failing to notify or seek approval for changes in a timely manner can result in compliance breaches, product recalls, or loss of authorization.
Post-approval activities typically include:
- Filing type IA, IB, and II variations for changes to the approved dossier
- Submitting PSURs and Periodic Benefit-Risk Evaluation Reports (PBRERs)
- Managing risk management plans and implementing label updates
- Tracking regulatory intelligence to identify changes that affect the product
- Supporting inspections and audits by health authorities
- Coordinating lifecycle management strategies to extend or expand the product’s market position
A well-maintained regulatory affairs function treats post-approval compliance as a strategic asset, not just an administrative burden. Proactive lifecycle management can open new indications, expand into new markets, and protect the product from unnecessary regulatory risk. Learn more about how we approach this through our team and expertise.
How Starodub supports your regulatory submissions
At Starodub, we provide end-to-end regulatory affairs support for biopharmaceutical and medical device companies navigating complex submission requirements. Whether you are preparing a first marketing authorization application, managing a portfolio of post-approval variations, or entering the EU market for the first time, we bring the expertise and structure to keep your program on track.
Here is what working with us looks like in practice:
- Regulatory strategy development: We assess your product, target markets, and data package to define the most efficient path to approval
- Dossier preparation and review: Our team drafts, compiles, and quality-checks CTD modules across all sections, including CMC, clinical, and nonclinical
- Health authority interactions: We prepare and coordinate scientific advice requests, manage agency communications, and respond to deficiency questions
- Post-approval lifecycle management: We handle variations, renewals, PSURs, and ongoing compliance monitoring so your authorization stays current
- Medical device regulatory support: From class I to class III devices, we support technical file preparation, notified body interactions, and EU MDR and IVDR compliance
- Flexible engagement models: We work as an extension of your internal team, with a single point of contact backed by collective expertise
With over 400 completed projects and more than 300 clients supported, we know what health authorities expect and how to deliver it efficiently. If you are ready to move your submission forward, get in touch with our team to discuss how we can support your regulatory program.
Related Articles
- How do you prepare a regulatory submission for the EMA?
- What Are the Key Pharmaceutical Regulatory Requirements in Europe?
- How do you navigate medical device regulations for combination products?
- What are the regulatory requirements for reprocessed single-use devices?
- What is the difference between FDA and EMA regulatory strategies?
This content was generated with the help of AI and it may contain mistakes